Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWC-20141 and DWC-20142 are small molecule drugs developed by Daewoong Pharmaceutical. They have been studied both individually and in combination, primarily for the treatment of digestive system disorders, including gastroesophageal reflux disease (GERD), mouth and tooth diseases, and otorhinolaryngologic diseases. The combination has undergone pharmacokinetic and drug-drug interaction studies in healthy volunteers. As of the latest updates, their development status is preclinical or phase 1 with no reported approvals or advanced clinical data available[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DWC-20141 + DWC-20142.